MyeloPro to announce non-dilutive early stage financing for developing drugs for rare blood malignancies

An FFG grant and aws Seedfinancing allow MyeloPro to complete the discovery program of mutant CALR targeting biologicals and to establish the necessary infrastructure for preclinical development. This is a major milestone for developing therapeutics to treat myeloproliferative neoplasms.

The non-dilutive federal funding allows MyeloPro to maintain independence and provides resources in addressing the high medical need of rare, orphan blood malignancies called myelopoliferative neoplasms (MPNs).

MyeloPro is a discovery stage, Vienna (Austria) based biopharmaceutical company, developing therapeutics to treat myeloproliferative neoplasms. MyeloPro obtained a worldwide, exclusive therapeutic license from CeMM of the Austrian Academy of Science to target the mutant form of calreticulin (CALR). MyeloPro is actively seeking private investor partners for preclinical development of its most promising development candidates.

Oleh Zagrijtschuk, MD
General Manager
Phone: +43 664 882 62 093
Email: oleh.zagrijtschuk(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)